Baseline disease characteristics
| Anakinra + MTX (n = 250) | Placebo + MTX (n = 251) | |
|---|---|---|
| Results are shown as mean (SD) | ||
| SD, standard deviation; MTX, methotrexate; CRP, C reactive protein; ESR, erythrocyte sedimentation rate. | ||
| Swollen joint count (0–66) | 20.1 (11.7) | 20.0 (10.2) |
| Tender or painful joint count (0–68) | 26.8 (15.7) | 24.5 (13.1) |
| Physician’s assessment of disease activity (0–100) | 57.4 (18.7) | 57.0 (18.4) |
| Patient’s assessment of disease activity (0–100) | 53.2 (22.1) | 52.3 (19.8) |
| Patient’s assessment of pain (0–100) | 59.2 (21.6) | 55.7 (20.4) |
| Health Assessment Questionnaire score (0–3) | 1.4 (0.6) | 1.3 (0.6) |
| CRP (mg/l) | 27 (26) | 26 (26) |
| ESR (mm/1st h) | 41.5 (22.3) | 42.9 (21.7) |
| Duration of morning stiffness (min/day) | 102 (84.3) | 111 (98.7) |